Kaerus Bioscience’s lead candidate KER-0193 has been granted both Orphan Drug Designation and Rare Pediatric Drug Designations for the treatment of Fragile X syndrome (FXS) by the US Food and Drugs Administration (FDA). This follows the recent successful completion of a Phase I trial of KER-0193 in healthy volunteers, which confirmed the drug to be […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!